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The clinical approach to patients with amyotrophic
lateral sclerosis (ALS) has been largely modiﬁed by the
identiﬁcation of novel genes, the detection of gene
mutations in apparently sporadic patients, and the
discovery of the strict genetic and clinical relation
between ALS and frontotemporal dementia (FTD). As a
consequence, clinicians are increasingly facing the
dilemma on how to handle genetic counselling and
testing both for ALS patients and their relatives. On the
basis of existing literature on genetics of ALS and of
other late-onset life-threatening disorders, we propose
clinical suggestions to enable neurologists to provide
optimal clinical and genetic counselling to patients and
families. Genetic testing should be offered to ALS
patients who have a ﬁrst-degree or second-degree
relative with ALS, FTD or both, and should be discussed
with, but not offered to, all other ALS patients, with
special emphasis on its major uncertainties. Presently,
genetic testing should not be proposed to asymptomatic
at-risk subjects, unless they request it or are enrolled in
research programmes. Genetic counselling in ALS should
take into account the uncertainties about the
pathogenicity and penetrance of some genetic
mutations; the possible presence of mutations of
different genes in the same individual; the poor
genotypic/phenotypic correlation in most ALS genes; and
the phenotypic pleiotropy of some genes. Though
psychological, social and ethical implications of genetic
testing are still relatively unexplored in ALS, we
recommend multidisciplinary counselling that
addresses all relevant issues, including disclosure of tests
results to family members and the risk for genetic
discrimination.
INTRODUCTION
In the last few years, the clinical approach to
patients with amyotrophic lateral sclerosis (ALS)
has been modiﬁed by the identiﬁcation of novel
genes, detected also in apparently sporadic cases,
and the discovery of ALS relationship with other
neurodegenerative diseases, in particular frontotem-
poral dementia (FTD). Furthermore, as for all
other genetic predisposition tests, genetic testing in
ALS may also become increasingly important at the
light of the future development of novel effective
therapies for speciﬁc genes.1
Patients and families, increasingly aware of the
genetic component of ALS, often ask about
genetic testing, even without an apparent family
history. Requests are also made by at-risk subjects,
namely, relatives of ALS patients or, less frequently,
for prenatal diagnosis. Neurologists need help in
handling the complexities underlying these
requests, since often decisions are made on indi-
vidual basis. The European Federation of
Neurological Societies (EFNS)2 has issued guide-
lines indicating that DNA analysis should be
limited to ‘cases with a known family history of
ALS, and in sporadic ALS cases with the character-
istic phenotype of the recessive D90A mutation’
and not performed in ‘cases with sporadic ALS
with a typical classical ALS phenotype’. EFSN
guidelines state also that ‘asymptomatic at-risk
genetic testing should only be performed in ﬁrst-
degree adult blood relatives of patients with a
known gene mutation, on a strictly voluntary basis
and following accepted ethical principles.’
Criteria for the classiﬁcation of familial ALS have
been recently proposed.3 They are based both on
the presence of ﬁrst-degree or second-degree rela-
tives with ALS and on the ﬁnding of genetic muta-
tions. The identiﬁcation of other neurodegenerative
disorders, in particular FTD, in patients pedigree,
is an additional criterion (see online supplementary
table 1).4 Despite this classiﬁcation, there is no con-
sensus among researchers about the deﬁnition of
familial cases.5
It has been advocated that the clinical genetic
approach in ALS can be modelled on the example of
Huntington disease (HD).6 However, while HD is a
monogenic disease (albeit with modifying genes),
usually with a positive family history and a rather
predictable penetrance, ALS is a polygenic disorder
with insufﬁcient data on penetrance and pathogen-
etic nature of many mutations. Furthermore, most
patients do not have a positive family history for
ALS or other neurodegenerative disorders.
This document is the result of a workshop on
ALS genetic testing in the clinical setting, held in
Corteranzo, Italy, 20–21 September 2012, by the
ITALSGEN Consortium. Participants were neurolo-
gists, geneticists, psychologists and ethicists, who
focused on producing a set of clinical, rather than
research, suggestions to optimise the communica-
tive process of genetic risk to ALS patients,
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including discussion of medical, psychological, social and ethical
implications.
Notably, reimbursement policies for genetic testing and coun-
selling vary in countries with a different health system, also on
the basis of the test required. In many countries, genetic testing
in apparently sporadic cases is not reimbursed. In the USA,
private insurances may deny reimbursement for genetic testing
or counselling, especially in the absence of effective preventive
or therapeutic measures. By contrast, in countries with socialised
medicine, such as Italy, the public health system covers most
instances of genetic testing and counselling, when requested by
a specialist and considered clinically relevant. Yet, since the basic
principles of genetic counselling, including its non-directiveness,
are similar across cultures, our clinical suggestions, while born
in the Italian context, are not limited to it and are intended for
professionals involved in ALS care.
THE DISEASE
ALS is a neurodegenerative disorder of adult life, characterised
by a progressive involvement of upper and lower motor neurons
at spinal and bulbar level. The diagnosis of ALS remains clinical,
supported by paraclinical exams.2 7 Currently, no speciﬁc bio-
markers of the disease are available, the only exception being
the ﬁnding of mutations of ALS-related genes and reduced
SOD1 dismutation activity.7 The only deﬁned risk factors are
older age and male gender. No ‘strong’ environmental factors
have been identiﬁed, possible exceptions being cigarette
smoking and slim body constitution.8 While ∼90% of patients
appear sporadically in the population, ∼10% of cases are famil-
ial in nature.4
ALS GENES: NOVEL DISCOVERIES AND NEW
UNCERTAINTIES
The list of ALS-related genes is rapidly increasing, mainly due to
the application of new technologies such as exome sequencing,
but also in relation to expansion of ALS DNA banks throughout
the world. About two-thirds of familial cases are caused by four
genes, C9ORF72, SOD1, TARDBP and FUS.4 9 At least 12 other
less common genes and loci are known (see online supplemen-
tary table 2); for the remaining cases, the genetic cause is still
unknown. However, wide areas of uncertainty persist also with
the best known gene mutations.
Frequency of ALS-related genes
The frequency of ALS-related genes is unevenly distributed in
different populations. For example, SOD1 mutations account
for ∼10% of ALS cases in Sweden and Finland, with the p.
D90A homozygous mutation being by far the most common
missense mutation,10 while they are found in less than 1% of
Dutch patients.11 Similarly, C9ORF72 is the commonest gene in
Caucasian populations,12 but is less frequent in patients of
Chinese or Japanese ancestry.13 14
Are all mutations pathogenic?
In many cases, we do not have a clear evidence of the patho-
genic role of some mutations. Even for SOD1, the most widely
studied gene, the demonstration of pathogenic nature of some
of the reported missense, nonsense and deletion mutations is
poor.10 A recent paper described four familial ALS pedigrees
discordant for two SOD1 mutations (p.D90A and p.E100 K),
raising questions about the heterogeneity of ALS in individual
pedigrees and the pathogenic nature of p.E100 K mutation.15
In the case of C9ORF72, the limitation comes from laboratory
techniques. Its pathogenic mutation is a GGGGCC
hexanucleotide expansion in the ﬁrst intron of the gene.
According to data from Southern blot analysis, the number of
repeats is up to more than 1000.16 However, in most laborator-
ies the expansion is searched with Sanger technology, not allow-
ing to identify more than ∼80 repeats.
How high is the penetrance of gene mutations?
In general, one problem in determining penetrance is that the
age-dependent likelihood of phenotypic manifestation of a
genetic mutation is often drawn from a population sample of
pooled data. When confronted with individual patients and
their families in a clinical setting, these data are difﬁcult to
apply, as each pedigree carries a speciﬁc penetrance, which may
shift across generations, due to marriage, other genetic modiﬁers
or anticipation phenomenon.
Additionally, speciﬁc data on the penetrance of different
mutations of ALS-related genes are still limited. For SOD1,
some mutations have a high penetrance (eg, p.A4V, homozygous
p.D90A) and others low penetrance (p.N19S, heterozygous p.
D90A, p.I113T).10 Several missense and nonsense mutations
have been described in single families or isolated patients, pre-
venting the possibility of drawing ﬁrm conclusions about their
penetrance. Mutations in the FUS gene seem to have quite a
high penetrance, while those of TARDBP probably vary accord-
ing to the involved codon. Data on C9ORF72 hexanucleotide
expansion are now starting to accumulate. A penetrance rate of
50% at 60 years, and an almost full penetrance at 80 years have
been estimated.12 Yet these ﬁgures should be considered with
caution since no systematic assessment has been performed in
large numbers of healthy controls of different ancestry. Two
other areas of uncertainty are whether a premutation size does
exist, and whether an anticipation phenomenon is present, simi-
larly to what is reported for other diseases with repeat
expansion.17
Is ALS an oligogenic disease?
Mutations of two ALS-related genes in the same patient are
increasingly described both in familial and apparently sporadic
patients,18 19–21 suggesting, at least in some cases, that multiple
genetic factors are necessary to develop ALS or determine its
phenotype.
Is there a genotypic–phenotypic correlation in ALS-related
genes?
Familial and sporadic ALS cases are clinically indistinguishable,
although some differences between gene-related phenotypes
have been identiﬁed. For example, C9ORF72 than any other
gene, is more frequently associated with comorbid FTD and
psychotic-like symptoms both in the index case and in the
extended family. Several other ALS-related genes may cause dis-
orders different from ALS (see online supplementary table 2).
FUS mutations are often characterised by a young age at onset
(<35 years), a rapid clinical course and death occurring within
18 months.9 SOD1 mutations are extremely heterogeneous, the
onset varying between the ﬁrst and the eighth decade, and rate
of progression going from very rapid (p.A4VV) to exceptionally
slow (p.G93D, p.L144F).10 Therefore, with few exceptions, the
clinical picture of a single patient cannot guide the genetic ana-
lysis, unless the gene has been already found in other family
members.
Are there susceptibility genes for ALS?
In sporadic patients, several genes and loci have been proposed
to be related to an increased risk, or to modify onset or
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progression. Only few of them have been replicated in inde-
pendent studies and in different populations, the most notable
being mutations of ATXN2, UNC13A, ANG, SMN1 and
SMN2.22 Reasons not to offer genetic testing for these muta-
tions in a clinical setting are: (1) none of them is necessary or
sufﬁcient to cause ALS, (2) molecular tests have low sensitivity
and speciﬁcity, (3) there are no feasible preventive options at
present and (4) it is difﬁcult to correctly convey a probabilistic
risk to patients and relatives with such high uncertainty.
FAMILIAL AND SPORADIC ALS: DOES THIS DICHOTOMY
STILL HOLD?
Classically, ALS cases have been distinguished between those
with a positive family history for ALS and those without other
cases in the family. However, this distinction does not hold
anymore. First, patients with and without genetic mutations do
not show any clear-cut clinical difference, with the possible
exception of those carrying the C9ORF72 expansion, who are
often associated with FTD, psychotic-like symptoms and extra-
pyramidal features. Second, pathogenic mutations of
ALS-related genes have been found, up to 10% in some series,19
in apparently sporadic ALS; a lack of family history is ascribed
to several factors, namely a non-informative family history, mis-
diagnosis of a relative, early death of relatives for other causes,
low gene penetrance, denial of the disease, non-paternity.22
Third, family size inﬂuences the probability of identifying other
affected members23 with members of small families having a
higher probability of appearing sporadic, particularly when
related to medium-low penetrance gene mutations. Fourth, rela-
tives of apparently sporadic ALS patients have an eightfold
increased risk of developing ALS compared with the general
population.24 Fifth, studies on twins have shown that heredit-
ability for ALS accounts for up to 60%, while environmental
factors account for the remaining 40%.25 Sixth, the possibility
of de novo mutations, occasionally demonstrated with FUS and
less commonly with SOD1.26 27
CLINICAL BOUNDARIES OF ALS AND THEIR RELATION TO
ALS HEREDITABILITY
The recent discovery of C9ORF72 expansions as the most rele-
vant mutation involved in both ALS and FTD, which can mani-
fest together in the same patient or coexist in the family, has
complicated the deﬁnition of ‘positive family history’.3 4
Clinically incomplete forms of motor neuron disease, that is,
progressive muscular atrophy (PMA) or primary lateral sclerosis
(PLS), are not included in the revised El Escorial classiﬁcation,
which has been conceived to be used for the selection of
patients for clinical trials.7 However, cases with pure PLS have
been described to occur within familial ALS pedigrees,28 and
patients with apparently sporadic PMA carry mutations of
ALS-related genes with a frequency similar to sporadic ALS
cases, demonstrating a genetic overlap between the three pheno-
types29; this aspect has been acknowledged by the revised El
Escorial classiﬁcation with the inclusion of the category of
‘Clinically deﬁnite familial–laboratory supported ALS’.7
PSYCHOLOGICAL, SOCIAL AND ETHICAL CONSEQUENCES
OF GENETIC TESTING
The identiﬁcation of a causal mutation in ALS patients has pro-
found effects on their family, since all biologic members may be
at risk of having inherited the mutation. The whole family may
experience emotional, psychological, ethical and legal implica-
tions.17 Psychological effects involve uncertainties about the pre-
dictivity of genetic testing, sometimes uninformative, for the
positive subject, concerns about relatives and different attitudes
toward sharing genetic information with family members.
Motivations to pursue a test are various and include the wish to
reduce anxiety, future and reproductive planning, lifestyle
changes,6 altruism in contributing to research and acquisition of
knowledge for the beneﬁt of offspring and relatives.30 Reasons
to refuse a predictive test include fear of the results, inability to
face the risk of developing the disease, wish to maintain hope,
desire to spare relatives worry if tested positive.6 Moreover, sub-
jects who are negative to a predictive test may experience a
feeling of isolation and estrangement up to a sense of guilt
toward their positive relatives (known as survivor guilt).31
DISCLOSURE OF GENETIC TEST RESULTS TO FAMILY
MEMBERS
The issue of disclosure of genetic knowledge to family members
will increasingly involve ALS patients and professionals. Studies
in oncology have shown that most mutation carriers are eager
to share the information, and often reconnect with distant
family members. Some, however, prefer not to disclose their
results due to estranged family relationships, unresolved con-
ﬂicts, perceived or actual vulnerability and receptivity of rela-
tives, or uncertainties about whether relatives would wish to be
informed.32 Professional ethics codes support the notion that
health professionals’ obligation is toward the patient, unless
there is a risk of serious harm to others, and concur that they
should respect their patients’ decisions with regard to disclos-
ure.33 Though no ‘Duty to Warn’ applies to genetic testing,34
physicians caring for ALS patients may be caught in a quandary,
especially when caring for more family members at once.35
They will require training and support in discussing these issues
with their patients and responding to relatives’ questions.36 The
American Society of Clinical Oncology, for example, urges
oncologists to clearly explain the nature of the genetic informa-
tion and its potential relevance to patients’ families, while
refraining from being judgmental, through repeat encounters
and proper counselling referrals.33
ETHICAL AND LEGAL IMPLICATIONS OF GENETIC TESTING
The ethical and legal implications of genetic testing include:
information and informed consent, right to be tested or not,
rights of others, patients’ and professionals’ responsibility to
share results with at-risk relatives, conﬁdentiality and privacy,
risk of discrimination, consequences of prenatal diagnosis, and
samples’ property and disposal. These issues have been widely
studied in the context of cancer susceptibility and continue to
be analysed as genetic testing becomes increasingly common
and complex, and is often unrelated to available preventive or
treatment measures.37–39
Genetic discrimination against asymptomatic individuals or
their relatives on the basis of actual or presumed genetic differ-
ences or characteristics has occurred in recent history.40
Mutation carriers can be subject to different forms and degrees
of discrimination in life or health insurance, at the workplace,
in the process of adoption or in seeking higher education. They
may also experience more subtle forms of estrangement and
rejection by their families or communities, being perceived as
less-than-ideal partners or parents. Similar concerns have also
been reported among genetic experts and oncologists.41 Issues
of genetic privacy and discrimination have been widely
addressed in their ethical aspects at national and international
level through regulatory measures and legislation.42 The Genetic
Information Nondiscrimination Act (GINA) in the USA and the
480 Chiò A, et al. J Neurol Neurosurg Psychiatry 2014;85:478–485. doi:10.1136/jnnp-2013-305546
Neurogenetics
 group.bmj.com on September 24, 2014 - Published by jnnp.bmj.comDownloaded from 
European regulation are examples of effective regulation applic-
able to ALS mutation carriers.43 44
AN ALGORITHM FOR GENETIC TESTING: CLINICAL
RELEVANCE AND AVAILABILITY OF AN EFFECTIVE
TREATMENT
In the clinical setting, genetic testing may be categorised accord-
ing to clinical relevance and availability of an effective treat-
ment.45 Clinical relevance is related to the test reliability to
predict a high risk for the disease, therefore including the
concept of high penetrance. An example of high clinical rele-
vance is Huntingtin (HTT) for HD, while of low clinical validity
is ApoE for Alzheimer disease. Availability of an effective treat-
ment refers to treatments that can cure, improve or prevent a
disease, as in phenylketonuria or Wilson’s disease (ATP7B gene).
Today, all ALS-related genes are characterised by the absence
of an effective treatment or preventive measures, although some
of them have a relatively high clinical relevance (ﬁgure 1).
Therefore, for asymptomatic at-risk relatives of ALS patients,
the absence of both dimensions does not justify the genetic test
on either medical and social grounds. On the contrary, in sub-
jects already affected by ALS, genetic testing is justiﬁed as a
support to the clinical diagnosis and, to a lesser degree, to
prognosis.7
CLINICAL SUGGESTIONS FOR GENETIC COUNSELLING AND
TESTING
It should be understood and discussed with all patients that,
once genetic testing is performed in one member (patient or
relative), the entire biological family is inevitably involved in the
genetic knowledge derived from the test of the index case, while
not all patients or at-risk relatives may wish to be tested or to
know the results of genetic testing. The ‘Right Not to Know’ is
a necessary corollary of the principle of autonomy and a basic
principle of human clinical genetics recognised by most inter-
national regulatory statements and legislation.30 44 It should be
noted, however, that in the ethical debate surrounding genetic
testing some authors claim that such a right amounts to a ‘Right
to Ignorance’ and is not an expression of true autonomy. They
rather invoke the individual’s responsibility to seek and share
genetic information in view of family and community ties. As
the issues of autonomy, right not to know, privacy and duty to
warn are now being revisited by authoritative sources, such as
the American College of Medical Genetics and Genomics in its
latest recommendations of March 2013, and—to a lesser extent
—by medical specialty societies, also neurologists and geneticists
involved in testing for ALS should become familiar with the
evolution of the ethical debate in clinical genetics in order to
provide appropriate counselling to their patients and family
members.38 39 46–50
Before proposing genetic testing, it is mandatory to obtain in
all ALS patients a detailed three-generation pedigree that cap-
tures the presence of ALS, FTD, other dementias, Parkinsonism
and psychiatric conditions. This should include age at disease
onset, diagnosis and age at death. Medical records and, if avail-
able, autopsy studies, are essential to clarify diagnoses. Patients
should be allowed to have an exhaustive discussion, with a
multidisciplinary team or an expert neurologist, about pros and
cons of the testing before giving their consent.
WHO SHOULD REQUEST THE GENETIC TESTING?
Genetic testing for symptomatic ALS patients should be
requested by a neurologist willing to take the responsibility to
interpret and communicate the results and their meaning to the
tested subject. Otherwise, the subject should be referred to dedi-
cated or referral centres with expertise in ALS for the testing
process. Genetic testing in asymptomatic at-risk subjects should
be requested by a neurologist in collaboration with a clinical
geneticist.
WHO SHOULD UNDERGO THE GENETIC TEST?
All ALS patients who have a ﬁrst-degree or second-degree rela-
tive with ALS, FTD or both, should be offered genetic testing.
Since at least 5–10% of apparently sporadic ALS patients carry a
mutation in known ALS genes and more are likely to be identi-
ﬁed in the future, genetic testing should be discussed also with
all other ALS patients, emphasising its still weak clinical signiﬁ-
cance and major uncertainties. These discussions will empower
patients and family members to make informed decisions about
whether or not to be tested or to enrol in clinical research pro-
tocols. At present, however, we do not recommend offering
genetic testing to sporadic ALS patients, outside research
protocols.
Genetic testing at present is not indicated in asymptomatic
at-risk subjects and, therefore, should not be proposed. When
requested by the subjects themselves, it should be performed
only within the framework of a standardised protocol for
asymptomatic at-risk testing in ALS expert centres. Genetic
testing can be performed in asymptomatic at-risk subjects for
research purposes, strictly following ethical guidelines for
informed consent and pre-test and post-test counselling.2
Careful consideration is needed when the asymptomatic
at-risk family members are children or adolescents. The recom-
mendations of the European Society of Human Genetics51 state
that ‘asymptomatic at risk genetic testing of minors for condi-
tions with adult-onset is acceptable only if preventive actions
(eg, therapeutic interventions) can be initiated before adult-
hood’. Therefore, at present, we absolutely discourage parents
Figure 1 Algorithm for genetic testing based on the two-dimensional
clinical relevance and availability of an effective treatment.44 When
referring to asymptomatic at-risk subjects, major ALS-related genes
(C9ORF72, SOD1, TARDBP, FUS) have a good clinical validity but no
treatment. Susceptibility genes (ATXN2, UNC13A, ANG, SMN1, SMN2)
have a low clinical validity and no treatment. AND, angiogenin; ApoE,
apolipoprotein E; ATP7B, ATPase Cu transporting beta polypeptide;
ATXN2, ataxin 2; C9ORF72, chromosome 9 open reading frame 72;
FUS, fused in sarcoma; HFE, high iron fe; HTT, Huntingtin; SMN1,
survival motor neuron 1; SMN2, survival motor neuron 2; SOD1,
superoxide dismutase 1; TARDBP, transactive response-DNA binding
protein.
Chiò A, et al. J Neurol Neurosurg Psychiatry 2014;85:478–485. doi:10.1136/jnnp-2013-305546 481
Neurogenetics
 group.bmj.com on September 24, 2014 - Published by jnnp.bmj.comDownloaded from 
from requiring ALS genetic analysis for their children, and rec-
ommend that the reasons for this conduct be explained, that is,
that genetic testing removes the child’s ability to make an
informed decision about testing when they reach adulthood,
and it carries major potential psychosocial implications.52 53
Similar considerations apply to preimplantation or prenatal
genetic testing for ALS, which are technically feasible as demon-
strated by anecdotal reports.54 55 Finally, as the clinical signiﬁ-
cance of genetic testing for disease predisposition, including
ALS, will increase, the ethical and psychosocial ramiﬁcations of
testing incompetent subjects will need to be reconsidered.39 56
WHY IS THE TEST REQUESTED?
For symptomatic subjects
At present, the main reason to request a genetic test in symp-
tomatic patients is to provide a diagnostic support. When pos-
sible, the detected mutation can be also used for prognostic
purposes and for future potential targeted therapeutic and/or
preventive measures. Genetic information will also help to eluci-
date molecular mechanisms underlying the disease.
For asymptomatic at-risk subjects
The usefulness of genetic testing for asymptomatic at-risk subjects
in the clinical setting is presently undetermined and, therefore,
related to future developments. Asymptomatic at-risk testing can be
proposed for research studies, provided that all relevant ethical
issues are considered and standards correctly applied.
HOW IS THE TEST OFFERED AND PRESENTED TO THE
PATIENT (PRE-TEST DISCUSSION)?
After a diagnosis of ALS is established, a discussion about ALS
genetics should be introduced in person, and meanings and lim-
itations of genetic tests explained in detail. A follow-up appoint-
ment should be offered for further questions. Patients will
receive an information leaﬂet only after a thorough discussion.
Informed consent
The informed consent must be exhaustive and include speciﬁc
statements related to present and future use of samples. In many
countries, long-term storage of DNA samples is forbidden by
legislation, and using clinical samples for research purposes is
generally not accepted both in the USA and Europe. In some
EU countries, long-term storage for clinical purposes is allowed
when clearly stated in the informed consent.44 Given the lack of
clear and uniform legislation on the difference between samples
for research and clinical purposes, and on disclosure of genetic
information, balancing privacy issues with potential advantages
and drawbacks of sharing clinical and research genetic data with
patients and their relatives, a strong partnership with patients
and families is key to maximising the individual beneﬁt of trans-
lation of genetic information, and to engage and educate
research participants.39 We recommend that, when allowed by
national regulation, each subject be asked to indicate in the
informed consent whether he/she agrees with sample storage
and its use for future genetic tests in case novel genetic muta-
tions related to ALS will be discovered. The subject will be
informed of the availability of new results and will be free to
decide whether to know them or not. In all cases, the subject
must indicate (1) if he/she wishes to know the results, (2) with
whom results could be shared by the professional, (3) to whom
results should be communicated in case of patient incapacitation
or death.
The presence of comorbid FTD in ALS patients should be
assessed in order to establish their decision-making capacity,
particularly regarding informed consent for genetic studies.56
A cognitive dysfunction not reaching the level of full-blown
dementia does not impair patients’ competence.57 In any case,
national regulations about competence should be carefully
applied.
Information leaﬂet
The information leaﬂet should include the following: (1) infor-
mation about ALS, (2) the purpose, nature and consequences of
the genetic testing, (3) risks involved in the procedure, (4) lim-
itations of test interpretation (eg, other not yet identiﬁed
Mendelian genes, genetic mutations that predispose to ALS), in
particular regarding C9ORF72,17 (5) practical information on
what will happen next, (6) potential harm of test, (7) potential
psychosocial, ethical and legal ramiﬁcations, (8) implications for
family members, (9) available resources, including those offered
by the ALS centre and (10) information on lay associations and
support groups. The information leaﬂet should be periodically
revised to reﬂect all signiﬁcant scientiﬁc and clinical advances.
Genetic testing in asymptomatic at risk subjects
If an at-risk relative of an ALS patient with a known genetic
mutation asks to undergo genetic testing, this should be per-
formed only after an accurate information process, including
discussion of present uncertainties of ALS genetics. In particular,
at-risk relatives should be made aware that even a positive test
does not provide reliable information about a future develop-
ment of the disease, age of onset, symptoms severity or progres-
sion rate.6
When a relative of an ALS patient with a positive family
history without known genetic mutation asks for a genetic test,
he/she should be informed that the DNA will be stored for
further analyses in case of future identiﬁcation of novel genes,
and should declare whether he/she wants to be informed of the
results. Phone numbers, mail or e-mail addresses, emergency
contacts and responsible professionals should be listed for the
person to be tested.
The process of genetic counselling: the role of a
multidisciplinary team
A multidisciplinary team, including neurologist, geneticist
and psychologist, is recommended for the management of
genetic counselling for asymptomatic at-risk subjects. Pretest
psychological assessment should be performed through: (a) psy-
chological interview(s), focused mainly on motivations, expecta-
tions and family dynamics; (b) speciﬁc psychological and
neuropsychological tests including assessment for personality,
depression, illness representation, suicidal tendency and cogni-
tive function.
WHERE AND HOW IS THE TEST PERFORMED?
Genetic testing should be performed in accredited medical gen-
etics laboratories according to international quality standards.58
Whenever possible, for each positive sample, a second test on a
new blood sample is recommended.
Both in-house developed and commercial assays should be
validated before use. The identiﬁcation of point mutation and
small del/ins is performed with Sanger sequencing method. For
expansions detection the Repeat Primed PCR (RP-PCR) proto-
col is followed.16
WHAT GENES SHOULD BE TESTED?
According to the available literature which mostly refers to
population of Caucasian or East Asian ancestry, two-thirds of
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mutations are found in four genes, C9ORF72, SOD1, TARDBP
and FUS. Therefore, these genes should be considered for a
routine diagnostic protocol. C9ORF72 testing is worthwhile in
sporadic patients as this gene has been shown to be present in a
signiﬁcant proportion of such cases, as well as in ALS patients
with relatives affected by FTD, while the other genes are more
rarely found in sporadic cases. If these four genes are negative,
second-level genetic analysis can be performed, assessing other
ALS-related genes, according to the country-speciﬁc genetic epi-
demiology when available. UBQLN2 should be tested in pres-
ence of a suspected X-linked dominant inheritance. The list of
genes should be periodically modiﬁed along with increasing
knowledge of ALS genetics.
In order to guide the genetic laboratory, the following demo-
graphic and clinical information should be provided by the
proponent physician: (1) gender, (2) age and site of onset,
(3) comorbidities (in particular FTD and extrapyramidal fea-
tures), (4) other members affected by ALS or FTD and their
relationship with the index case, (5) ethnicity, (6) place of birth
and area of origin of parents and grandparents. This informa-
tion is very important to avoid the risk of inadvertently per-
forming an asymptomatic at-risk test outside the proper
counselling context and procedures.
Although some genes have been proposed as ALS modiﬁers
(ie, ATXN2, UNC13A, SMN1 and SMN2), these should not be
performed for clinical purposes, but reserved only for the
research setting.
WHAT INFORMATION SHOULD BE INCLUDED IN THE
GENETIC REPORT?
The report should contain demographic information, detailed
list of the genes tested and the exons analysed for each gene,
test methodologies, limitations of each methodology (false posi-
tive and negative percentage) and explanation of the genetic
ﬁndings. Unreported genetic variants should be discussed in
order to distinguish, when possible, mutations from non-
pathogenetic polymorphisms.
HOW ARE THE RESULTS HANDLED BY THE PROPONENT
PROFESSIONAL (POST-TEST DISCUSSIONS)?
The results of the genetic test, either positive or negative,
should be communicated in person to the patient by the pro-
ponent professional, and never by letter, e-mail or phone.
Ideally, discussions of genetic test results with asymptomatic
at-risk subjects should take place in a team context, with the
concomitant or subsequent presence of a geneticist and a psych-
ologist. As this may be unfeasible in many clinical settings, we
recommend as minimal requirement that test result discussions
be performed by a neurologist skilled in ALS genetics. All tested
subjects are encouraged to be accompanied by a trusted family
member or friend to help support them in the processing of the
information received. The patient should be given time to
process the information and ask questions, and a follow-up
appointment should be organised for further questions.
Psychological support should be offered to the patient tested
and to at-risk relatives informed by the patient.
Conﬁdentiality
Results of genetic testing are highly sensitive, and rigorous mea-
sures to ensure conﬁdentiality are necessary. Results must never
be disclosed to a third party without explicit written consent
from the patient or their lawful surrogates. To avoid uninten-
tional disclosure, test results must be kept in a separate ﬁle and
not in the patient’s medical records.2 However, this measure
could be modiﬁed over time, when genetic testing will be better
understood in its clinical meaning and limitations rather than in
a deterministic way that equates genetic knowledge with the
notions of ‘future diaries and destiny’.38 59 Also, gene therapy
for many diseases, including ALS, may become available in
the future, and withholding information could prevent patients
and/or family members from receiving effective treatment
measures.
CONCLUSIONS
Genetic information about ALS is rapidly growing but not yet
fully translated into clinically useful knowledge. While we could
be tempted to refrain from discussing with our patients about
information that is already exceeding our comfort level as pro-
fessionals, we must, however, consider the potential beneﬁts of
genetic information for patients’ autonomy. Despite major cul-
tural, social and religious differences among different popula-
tions that prevent generalisations about attitudes and practices
related to genetic testing and the universal applicability of clin-
ical recommendations, the communication process that accom-
panies and follows genetic testing for ALS should be
standardised following existing clinical experiences and guide-
lines in neurologic and other diseases. Further research in clin-
ical and epidemiological genetics of ALS is urgently needed to
improve the process of genetic counselling for our patients
(box 1). The aim of our clinical suggestions is to enable neurolo-
gists and ALS specialists to provide optimal multidisciplinary
clinical consultations to our patients and families.
In the future, we may increasingly be asked to consult on
genetic tests recommended or prescribed by other physicians, or
obtained through direct-to-consumer tests. Requests for testing
asymptomatic minors, and for prenatal diagnosis, are also likely
to increase. It is therefore our professional duty as ALS experts
to be constantly updated about the developments in our ﬁeld, to
help reﬁning and updating clinical suggestions and recommen-
dations based on new genetic knowledge, and to promote con-
tinuous medical education in all its medical and communicative
aspects.
Box 1 Priority areas for amyotrophic lateral sclerosis
(ALS) research in clinical genetics and genetic counselling
A. ALS clinical genetics
▸ Identiﬁcation of the pathogenicity of different ALS genes
and, in each gene, of different mutations.
▸ Identiﬁcation of penetrance of different genes/mutations.
▸ Identiﬁcation of cut-off size of pathogenic GGGGCC
expansion in C9ORF72 gene.
▸ Identiﬁcation of genetic-phenotypic correlations of
different ALS genes/mutations.
▸ Identiﬁcation of frequency of ALS-related genes/mutations
in various populations.
B. Genetic counselling in ALS
▸ Identiﬁcation of psychological, social and ethical factors
implicated in genetic counselling of ALS patients and their
relatives, including asymptomatic at-risk subjects.
▸ Quality assessment of genetic counselling process in the
context of ALS patients and presymptomatic subjects
testing.
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